Domov › Steatotična bolezen jeter › Pennsylvania
Klinične študije za Steatotična bolezen jeter v Pennsylvania
5 študij za Steatotična bolezen jeter išče udeležence na lokacijah v Pennsylvania.
Mesta v Pennsylvania
Uradno besedilo študije (angleško)
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
- 89bio Clinical Study Site, Philadelphia
- 89bio Clinical Study Site, Pittsburgh
Vključevanje udeležencevFaza 3
Starost 18–75 · Vsi spoli · Posodobljeno 5. okt. 2026 · NCT06419374A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
- Geisinger Medical Center, Danville
- Penn State Health Milton S. Hershey Medical Center, Hershey
- University of Pennsylvania - Perelman Center for Advanced Medicine, Philadelphia
Vključevanje udeležencevFaza 2
Starost 18–75 · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT05519475A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- US Digestive Health - Flourtown, Flourtown
- Penn Medicine: University of Pennsylvania Health System, Philadelphia
- US Digestive Health - Wyomissing, Wyomissing
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT07165028A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
- Akero Clinical Study Site, Hershey
- Akero Clinical Study Site, Philadelphia
- Akero Clinical Study Site, Philadelphia
- in še 1
Vključevanje udeležencevFaza 3
Starost 18–80 · Vsi spoli · Posodobljeno 21. sep. 2026 · NCT06528314A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
- GSK Investigational Site, Philadelphia
Vključevanje udeležencevFaza 2
Starost 18–70 · Vsi spoli · Posodobljeno 3. avg. 2026 · NCT06613698Vir: ClinicalTrials.gov, podatki pridobljeni 6. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.